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antibiotics. A four-drug regime without rifampicin given forSuccessful management of pulmonary tuberculosis in renal al-
18 months is effective for pulmonary tuberculosis in patientslograft recipients in a single center.
on cyclosporine. We recommend routine prophylactic use ofBackground. Pulmonary infections, especially tuberculosis,
one single-strength tablet of cotrimoxazole daily for at leastare responsible for significant mortality and morbidity among
six months after transplantation.renal transplant recipients in developing countries. Conven-
tional diagnostic modalities are associated with a low yield,
delaying specific therapy.
Methods. All patients transplanted within a 1.5-year period Infections are a major barrier to successful long-term
were prospectively followed-up for one year. Patients were on
outcome of renal transplantation, especially in devel-a cyclosporine-based triple immunosuppressive regimen. None
oping countries. Life-threatening opportunistic infec-received isoniazid prophylaxis, and those transplanted in the
tions are encountered most often in the first post-trans-last seven months of the study period received daily cotrimoxa-
zole. Patients exhibiting unequivocal evidence of pulmonary plant year, and they frequently involve the lung [1, 2].
infections underwent further evaluation. Search for offending Early diagnosis is crucial, as the mortality is increased
organisms was made by sputum examination and bronchoal- by a delay in the identification of the etiologic agent andveolar lavage (BAL).
the start of effective therapy [3]. The etiological spectrumResults. Thirty-nine infection episodes were recorded in 34
of infections is well defined in the Western nations andpatients. M. tuberculosis was isolated during 10 episodes, pyo-
genic bacteria and Pneumocystis carinii in 6 each, candida in helps in the diagnosis, treatment, and planning of preven-
4, aspergillus in 3, cytomegalovirus (CMV) in 3, and nocardia tive strategies [4–6].
and mucor in one episode each. More than one organism was The nature of pulmonary infections encountered inisolated during five episodes. Bacterial pneumonia and tuber-
transplant recipients in underdeveloped countries hasculosis were diagnosed in another seven and two patients, re-
not been studied systematically. Retrospective studiesspectively, on the basis of a therapeutic response to specific
chemotherapy. Over two thirds of the organisms were identi- have shown a high frequency of tuberculosis and fungal
fied by examination of BAL fluid. BAL was useful in the infections, whereas others, such as cytomegalovirus
diagnosis of tuberculosis and P. carinii pneumonia but was (CMV) and Pneumocystis carinii, are not well recognized
relatively insensitive for CMV and bacterial infections. An
[7–12]. The use of conventional diagnostic modalities isincreased frequency of acute rejection and higher serum creati-
associated with a low rate of isolation of organisms, withnine were factors that predisposed to infections. All patients
with pulmonary tuberculosis made a full recovery. a resultant increase in the hospital stay, morbidity, and
Conclusions. Tuberculosis and P. carinii are the most com- mortality [7, 10].
mon nonpyogenic infections in the first year after transplanta- We undertook a prospective study to define the nature
tion in developing countries. An aggressive search for tubercle of pulmonary infections in the first year after renal trans-bacilli should be made using bronchoscopy and examination
plantation using bronchoscopy and bronchoalveolar la-of BAL fluid in patients not responding to a short trial of
vage (BAL), and to assess its impact on diagnosis and
therapy. This communication documents the results of
Key words: kidney transplantation, pulmonary infection, bronchoal- this study.
veolar lavage, cyclosporine, cotrimoxazole.
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for one year. Patients referred for follow-up to our center therapy and/or documentation of invasive fungal infec-
tion on histology were required for diagnosis of fungalwithin one month of transplantation elsewhere were also
included. A pretransplant workup included a screening infections.
Patients presenting with pleural effusion underwent afor pre-existing infections, including the Mantoux test
and enzyme-linked immunosorbent assay (ELISA) for paracentesis, and the fluid was analyzed for protein and
sugar content, cell counts, stained with gram and Ziehlhuman immunodeficiency virus (HIV). A past history of
tuberculosis was recorded. Nielsen stains and put up for cultures. Pleural biopsy
was performed in two patients. Lung tissue was studiedAll patients received triple-drug immunosuppression.
Cyclosporine A was started at 8 mg/kg/day and was re- histopathologically in five of the seven patients who died
(3 at autopsy and 2 by postmortem lung biopsy).duced by 1 mg/kg every month to 4 to 5 mg/kg/day. The
starting dose of prednisolone was 0.5 mg/kg/day, tapered Patients suspected to have bacterial pneumonia on
clinical grounds were treated empirically with ciproflox-to 0.15 to 0.175 mg/kg/day by six months, and azathio-
prine was administered at 1 mg/kg/day. Rejection was acin or amoxycillin clavulanate. The drug was changed
if there was no response in 72 to 96 hours or if culturediagnosed using standard criteria and was treated with
500 mg intravenous methylprednisolone or 300 mg oral results demonstrated sensitivity to another antibiotic.
The infected and noninfected groups were comparedprednisolone daily for three to five days. The diagnosis
was confirmed by graft biopsy whenever possible. None for the frequency of factors that could have predisposed
to pulmonary infection, namely, frequency of acute rejec-of the patients received OKT3, ATG, or ALG. In contin-
uation of our earlier policy, no prophylaxis was given tion, serum creatinine, cumulative steroid dose, and nu-
tritional status, as indicated by body mass index andfor P. carinii. Eleven months into the study, however,
after six cases with this infection were diagnosed, all serum albumin. An analysis was done using x2 test for
ordinal data and Student’s unpaired t-test for continuouspatients were started on one single-strength tablet of
cotrimoxazole per day. No patient received isoniazid data. A P value of ,0.05 was considered significant.
(INH) prophylaxis.
All patients presenting with fever, cough, pulmonary
RESULTS
infiltrates, and hypoxia, either alone or in combination,
Study population and outcomeunderwent further evaluation. Patients with involvement
limited to the upper airways and/or infiltrates caused by Eighty-two patients were transplanted at our center
during the study period. Five patients followed up afternoninfectious causes were excluded.
The workup included complete blood counts, bio- transplantation elsewhere were also included in the
study. Six patients either died of noninfectious causes inchemical screen, blood cultures, and chest skiagrams re-
peated as often as necessary. High-resolution computed the first month or went elsewhere for follow-up and,
hence, were excluded from final analysis.tomography scan of the chest was performed in five pa-
tients. The sputum was stained with gram stain, Ziehl- Out of the 81 patients followed up, 77 had received
their grafts from living related donors and 4 (all trans-Nielsen stain, and silver methenamine stain on three
consecutive days and was cultured. Patients in whom planted elsewhere) from living unrelated (paid) donors.
All were HIV negative, and three had been treated forsputum was scanty or nondiagnostic underwent BAL.
Bronchoscopy was performed with Olympus broncho- tuberculosis in the distant past. The pretransplant Man-
toux test was 10 to 20 mm in four patients. None ofscopes (Models 2-T-10 and 20; Olympus America, Mel-
ville, NY, USA). After topical lidocaine administration, these were treated for tuberculosis. Four patients were
detected to have tuberculosis in the pretransplant periodthe scope was passed intranasally and wedged either into
the distal airway of the most involved segment deter- and were on antitubercular chemotherapy (ATT) for
periods ranging from six weeks to three months at themined by chest x-ray or into one of the basal segments
of the right lower lobe. Thirty milliliter aliquots of sterile time of transplantation. In view of interference with
cyclosporine metabolism, rifampicin was discontinuednormal saline were instilled and aspirated to a total of
120 ml. The lavage fluid was stained and cultured for one week before transplantation, and the rest of the
ATT with at least three bactericidal drugs was continued.bacteria, acid-fast bacilli (AFB), and fungi including P.
carinii. Fluid was also stained with Giemsa’s stain to These patients were considered to be not at risk of devel-
opment of tuberculosis during the study period.identify cells containing CMV inclusion bodies. Bacterial
infection was diagnosed if more than 104 cfu/ml of an Thirty-nine episodes of pulmonary infections were
noted in 34 patients (group I). Three patients had twoorganism were grown. P. carinii pneumonia was diag-
nosed by identifying the trophozoites on Wright-Giemsa and one had three episodes. The demographic character-
istics of these patients and those without pulmonary in-stain or cyst forms on methenamine silver or calcofluor
plus stains. Demonstration of a positive culture along fections (group II) are given in Table 1. The overall one-
year patient and graft survivals were 86.4% and 81.5%,with compatible radiology and response to antifungal
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Table 2. Organism isolated from patients with pulmonary infectionsTable 1. Demographic characteristics of patients with
post-transplant pulmonary infections
Organism Total no. Isolated on BAL
Parameter Group I Group II
M. tuberculosis 10 8
P. carinii 6 4No. of cases 34 (42%) 47 (58%)
Sex ratio male:female 28:6 35:12 Candida 4 4
Aspergillus 3 2Age years 36.2867.24 34.4869.11
Range 19–56 17–51 Pseudomonas 3 3
S. aureus 2 2Donor source
Living related 31 46 Klebsiella 1 0
Cytomegalovirus 3 0Living unrelated 3 1
1-year patient survival 79.4% 91.5% Nocardia 1 1
Mucor 1 01-year graft survival 73.5% 87.2%
More than one organism was isolated during 5 episodes (one each with P. car-
inii 1 Candida 1 Nocardia, tuberculosis 1 P. carinii, CMV 1 Aspergillus, CMV 1
P. carinii and CMV 1 Candida). Abbreviation BAL is bronchoalveolar lavage.
respectively, with 60% of the deaths occurring in group 1
(Table 1).
P. carinii was isolated in six patients. All of these pa-
Presenting features and roentgenographic appearances tients were seen in the first 11 months of the study. Bron-
choscopy could not be done in two who died of respiratoryFever (93%) and cough (56%) were the common pre-
senting symptoms. Sputum production was observed in failure within 36 hours of arrival, and the organism was
demonstrated on postmortem lung aspiration.only 23% cases. Roentgenographic abnormalities were
noted during 38 episodes (unilateral in 25 and bilateral Fungi were the sole infecting agents in five patients.
The diagnosis was made on histological demonstrationin 13). Lobar or segmental air-space consolidation was
most frequently associated with bacterial pneumonia. of organisms at autopsy in one patient each with aspergil-
lus and mucor infections. In another case, candida al-Patients with aspergillosis showed nodular shadows, but
the radiological appearances were not specific in other ready isolated on BAL was further confirmed at autopsy.
Five patients recovered following treatment with ampho-cases. Apical infiltrates were seen in only two patients
with tuberculosis. tericin-B or fluconazole. Of the three who died, two
showed coinfection with CMV at autopsy.A total of 31 bronchoscopies was performed during
28 infection episodes. None of the patients experienced Bronchoalveolar lavage was not done during 11 epi-
sodes. These included three patients who died before aany complication. Thirty-four organisms were isolated
(Table 2), 24 on BAL, 3 on sputum analysis, and 7 at detailed work-up could be done, three in which sputum
examination yielded the diagnosis, four who respondedpostmortem examination.
to empiric antimicrobial therapy, and one patient with
Type of infections pleural effusion who responded to ATT.
Bronchoalveolar lavage was nondiagnostic in eight in-Bacterial pneumonia was diagnosed in 14 cases, in 7
by isolation of organisms, and in the rest by observing stances. These included three patients with CMV infec-
tion and one with mucor. Another four patients im-a clinical and radiological response to antibacterial ther-
apy. AFB were demonstrated in 10 of 77 (13%) patients proved on changing the therapy, three with antibacterials
and one on ATT. In one patient who died 18 days intowho were at risk of developing tuberculosis. In two other
patients who had presented with prolonged fever, one the illness, the exact diagnosis could not be established.
No etiology could be found in three patients with feverwith bilateral midzone infiltrates and the other with exu-
dative pleural effusion, no organism could be found, despite an intensive work-up. Two of these patients with
pyrexia of unknown origin later responded to ATT, anddespite extensive investigations, including BAL and
pleural biopsy. Both patients responded to a trial of one died undiagnosed.
ATT, thus retrospectively suggesting the diagnosis of
Time of infectionstuberculosis. None of the patients showed clinical evi-
dence of involvement of extrapulmonary site. The pre- Over 45% of infections occurred during the first four
months after transplantation (Fig. 1). All infections en-transplant Mantoux test was negative in all but one of
these patients. None of the patients who were on ATT countered in the first month were bacterial pneumonias.
All cases of P. carinii pneumonia were seen in the firstat the time of transplant developed a flare of the disease.
All patients received a four-drug regime consisting of six months after transplant. Fungal infections tended to
occur after the first three months. Patients with tubercu-INH, pyrazinamide, ethambutol, and ciprofloxacin for
18 months [7]. Two patients developed INH-induced losis were distributed evenly throughout the year.
The frequency of acute rejection episodes and meanhepatitis after three and five weeks, requiring temporary
withdrawal of the drug. None of the patients died. serum creatinine at the time of onset of infection was
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Fig. 1. Showing the time at which infection (r)
and rejection (X) episodes occurred in all group
1 patients.
Table 3. Comparison of predisposing factors between the infected episodes, but the difference did not reach statistical sig-
and noninfected groups nificance. The body mass index and serum albumin levels
Group I Group II were similar in the two groups. Similarly, the incidence
Parameter (N 5 34) (N 5 47) P value of leukopenia, post-transplant diabetes, and hepatic dys-
No. of rejection episodes 1.09 60.86 0.6660.79 0.023 function was not significantly increased in the group with
Maximum serum infection. Within the two groups, there was no differencecreatinine mg/dl 2.2260.93 1.7760.67 0.0063
in these parameters between the patients not receivingCumulative prednisolone
dose at 1 year g 7.1661.59 6.4861.55 0.055 cotrimoxazole prophylaxis and those in whom it was
Serum albumin g/dl 3.3260.40 3.4460.47 .0.05 given in the later part of the study.Body mass index 20.81 62.04 21.4562.29 .0.05
Leukopenia 4 2 .0.05
PTDM 3 1 .0.05
DISCUSSIONLiver dysfunction 4 1 .0.05
Anemia (Hb , 8) 3 0 .0.05 As many as 42% of the patients developed pulmonary
Abbreviations are: PTDM, post-transplant diabetes mellitus; Hb, hemoglobin. infections in the first post-transplant year in this prospec-
tive study. This figure is higher than the 6 to 26% inci-
dence noted in retrospective studies from the Western
countries [3, 5, 6, 12–17]. The reasons include differences
higher in the patients with infection compared with the in immunosuppressive protocols, the use of prophylactic
noninfected group (Table 3). Rejection was confirmed antimicrobials, the duration of follow-up, and socioeco-
at biopsy in 54% of patients with infection and 45% of nomic factors. Noninfectious causes such as congestive
noninfected cases. In most patients, rejection episodes cardiac failure, pulmonary hemorrhage, embolism, and
preceded the development of pulmonary infections malignancies that can mimic pulmonary infections [18, 19]
(Fig. 1). The maintenance dose of both cyclosporine and were carefully excluded in this study. Fever, seen in over
steroids was not significantly different between groups 90% of cases, provided a strong clue to an infective
at any time. The infected group had received a higher etiology. However, fever has also been noted in patients
with post-transplant pulmonary edema [5].cumulative dose of steroid on account of the rejection
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Table 4. Frequency of etiologic agents causing pulmonary infections in renal transplant recipients
Ramsey et al [3]
Munda Webb Simmons Edelstein Cazzadori Moore Sternberg Hedemark Present
et al [6] et al [15] et al [5] Primary Secondary et al [12] et al [13] et al [16] et al [32] et al [19] study
No. of episodes 46 44 22 36 23 32 40 17 48 52 39
Organism frequency (% of all infection episodes)
CMV 15.2 9.1 45.4 22.2 0 0 10 47.1 16.7 50 7.7
Pyogenic bacteria 73.9 84 40.9 33.3 60.8 71.9 5 47.1 20.8 17.3 33.3
M. tuberculosis 4.3 0 0 0 8.6 28.1 7.5 0 0 3.8 30.8
Nocardia 0 13.6 0 22.2 0 0 0 5.9 6.3 0 2.6
Legionella 0 0 0 0 0 0 0 5.9 8.3 0 0
P. carinii 13 6.8 4.5 2.8 4.3 0 2.5 23.5 6.3 0 15.4
Aspergillus 2.2 6.8 0 13.9 13 0
12.5
11.8 0 19.2 7.7
Candida 4.4 4.5 0 2.8 4.3 0 0 2.1 0 10.2
Cryptococcus 4.4 4.5 0 2.8 4.3 0 0 0 2.1 1.9 0
Othersa 4.4 0 0 2.8 26.1 0 0 5.9 6.3 5.7 2.6
a Include mucor, histoplasma, coccidioides, toxoplasma, torulopsis, chlamydia, herpes and influenza
A variety of organisms can cause pulmonary infections [3, 5, 6, 12, 13, 16, 17, 19, 31, 32], most frequently one
in transplant recipients (Table 4). A total of 15.6% of to four months after transplantation [3]. As in this study,
patients developed pulmonary tuberculosis in this study. candida develops as part of polymicrobial infection fol-
A positive bacteriological diagnosis was made in 83% lowing the use of broad-spectrum antibiotics [3].
of cases, much better than the 37 to 50% isolation rate Conventional radiology alone is seldom helpful in
of this organism using conventional techniques [7–12]. post-transplant pulmonary infections. A homogeneous
The incidence of this infection among transplant recipi- lobar or segmental consolidation may suggest bacterial
ents has been reported to be 0 to 3% in Europe and pneumonia [6, 16, 17], but invasive techniques are needed
America [20–24], 3.5% in the Middle East [25], 4% in for making an accurate diagnosis in nonbacterial infec-
Turkey [11], and 7% in South Africa [12]. Pleuro-pulmo- tions. These include transtracheal aspiration [6], BAL
nary tuberculosis was seen in only 5% of transplant recip- [13, 32–35], percutaneous needle aspiration [36], trans-
ients during 1985 to 1990 at our center [7]. Thus, this bronchial lung biopsy [13], and open lung biopsy [6].
study shows a further increase in the incidence to more This study demonstrates that BAL is very sensitive for
than 100-fold over the general population in India, in tuberculosis, P. carinii, and fungal infections. In a pro-
whom a positive Mantoux test indicating past exposure spective study among AIDS patients, Golden et al found
to the organism can be documented in 30 to 70%, and the sensitivity of BAL to be 97% for P. carinii [34].
0.13% develop tuberculosis every year [26]. It is possible Cazzadori et al found BAL and transbronchial biopsy
that cyclosporine could have led to early recrudescence (TBB) equally efficacious for P. carinii pneumonia and
of tuberculosis in patients harboring dormant tubercle tuberculosis, but TBB was superior for pyogenic, fungal,
bacilli [27]. Cyclosporine interferes with release of in- and CMV infections [13]. The low yield of CMV could
terleukin-2 (IL-2) and tumor necrosis factor-g (TNF-g)
be as a result of patchy involvement or because therequired for clonal expansion of lymphocytes and migra-
infected cells are not shed into alveoli and thus not recov-tion and activation of macrophages that destroy and/or
ered in the lavage. As in this study, empiric antibacterialsequester the mycobacteria [28, 29]. Blockage of these
therapy prior to fiberoptic bronchoscopy impairs the di-lymphokines can lead to unchecked multiplication and
agnostic yield of BAL for bacterial infections [32, 37].the spread of dormant bacilli. The same mechanism
In renal transplant recipients with pulmonary infiltratescould lead to cutaneous anergy, making the Mantoux test
in whom the BAL is inconclusive, the next step shouldunhelpful as a diagnostic test [28, 29]. This hypothesis,
be a TBB. Alternatively, or if TBB does not yield ahowever, needs to be tested in experimental studies.
diagnosis, open lung biopsy under local anesthesia andOur study documents the emergence of P. carinii
endotracheal intubation should be performed [6, 13].pneumonia among cyclosporine-treated renal transplant
Where the organism still cannot be isolated and clinicalrecipients in an area from where it has been previously
suspicion of tuberculosis is strong, a three- to six-weekunreported. P. carinii has been reported only rarely in
trial of ATT under close monitoring can be consideredthe Indian transplant population [30], and most centers
in areas endemic for tuberculosis [7].do not administer any prophylaxis against this organism.
An increased frequency of rejections and worse renalCotrimoxazole prophylaxis was effective in preventing
function emerged as factors that could have predisposedthis infection and we believe it should be administered
to infections. The incidence of CMV infection could havefor at least six months to all transplant recipients on
been underestimated in this study because of the non-cyclosporine. Fungal infections of the lung have been
reported in 0 to 43% of cases after renal transplantation availability of modern serological techniques. Malnutrition,
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trand CM, Najarian JS: Pulmonary complications in renal trans-another potential predisposing factor, was seen with
plant recipients. Arch Surg 105:260–268, 1972
equal frequency in both the groups. 6. Munda R, Alexander JW, First MR, Gartside PS, Fidler JP:
Pulmonary infections in renal transplant recipients. Ann SurgMortality in renal transplant recipients with pulmo-
187:126–133, 1978nary infections has been reported to be 16 to 42% [5, 6,
7. Sakhuja V, Jha V, Varma PP, Joshi K, Chugh KS: The high
12, 13, 16, 17, 19, 31, 32] and exceeds 95% when the incidence of tuberculosis among renal transplant recipients in In-
dia. Transplantation 61:211–215, 1996infection complicates a pre-existing pulmonary disease
8. Agarwal SK, Dash SC, Tiwari SC, Agarwal R, Mehta SN:[3]. The figure of 21% in our study compares favorably
Spectrum of tuberculosis in renal transplant recipients in North
with these reports. Most of the deaths were caused by India. Ind J Nephrol 2:39–43, 1992
9. Malhotra KK, Dash SC, Dhawan IK, Bhuyan UN, Gupta A:CMV and P. carinii pneumonia. The outcome was much
Tuberculosis and renal transplantation: Observations from an en-better in whom the organism could be identified early
demic area of tuberculosis. Postgrad Med J 62:359–362, 1986
using the aggressive diagnostic approach described here, 10. Chugh KS, Sakhuja V, Jain S, Singh V, Tarafdar A, Joshi K,
Gupta KL, Minz M: Fungal infections in renal allograft recipients.permitting prompt institution of therapy. A notable fea-
Transplant Proc 24:1940–1942, 1992ture was the complete recovery of all patients with tuber-
11. Yildiz A, Sever MS, Tu¨rkmen A, Ecder T, Besisik F, Tabak L,
culosis, probably as a result of the institution of therapy Ece T, Kilic¸arslan I, Ark E: Tuberculosis after renal transplanta-
tion: Experience of one Turkish center. Nephrol Dial Transplantbefore the bacillary load became high. In earlier studies,
13:1872–1875, 1998the mortality in post-transplant tuberculosis has varied
12. Edelstein CL, Jacobs JC, Moosa MR: Pulmonary complications in
from 15 to 27% [7, 11, 27]. Furthermore, the absence of 110 consecutive renal transplant recipients. S Afr J Med 85:160–163,
1995any recrudescence of disease in those on ATT at the
13. Cazzadori A, Di Perri G, Todeschini G, Luzzati R, Boschierotime of transplant suggests that it is safe to undertake L, Perona G, Concia E: Transbronchial biopsy in the diagnosis
transplantation in chronic renal failure (CRF) patients of pulmonary infiltrates in immunocompromised patients. Chest
107:101–106, 1995with tuberculosis, provided they have received ATT for
14. The Canadian Multicenter Transplant Study Group: A ran-at least six weeks. Only three (37%) patients with fungal domized clinical trial of cyclosporine in cadaveric renal transplanta-
infections died, of whom two showed disseminated CMV tion. N Engl J Med 309:809–815, 1983
15. Webb WR, Gamsu G, Rohlfing BM, Thorburn K, Kalifa LG,infection at autopsy. This figure is a vast improvement
Amend WJ, Roberts M, Salvatierra O Jr: Pulmonary complica-over 63% mortality reported in systemic fungal infec- tions of renal transplantation: A survey of patients treated by low-
tions among renal transplant recipients reported earlier dose immunosuppression. Radiology 126:1–8, 1978
16. Moore EH, Webb WRM, Amend WJC: Pulmonary infections infrom our center [10]. In addition, we were able to shorten
renal transplant recipients treated with cyclosporine. Radiologythe hospital stay and reduce the morbidity by making a 167:97–103, 1988
specific etiologic diagnosis. This emphasizes the need for 17. Peterson PK, Ferguson R, Fryd DS, Balfour HH, Rynasiewicz
J, Simmons RL: Infectious diseases in hospitalized renal transplantearly bronchoscopy and BAL to look for the causative
recipients: A prospective study of a complex and evolving problem.organisms, especially tuberculosis in endemic areas. Medicine (Baltimore) 61:360–372, 1982
In conclusion, tuberculosis and P. carinii are the most 18. Rosenow EC, Wilson WR, Cockerill FR: Pulmonary disease in
the immuno-compromised host. Mayo Clin Proc 60:437–487, 1985common opportunistic organisms encountered in the
19. Hedemark LL, Kronenberg RS, Rasp FL, Simmons RL, Petersonfirst year following transplantation. An aggressive ap- PK: The value of bronchoscopy in establishing the etiology of
proach using bronchoscopy with BAL significantly in- pneumonia in renal transplant recipients. Am Rev Respir Dis
126:981–985, 1982creases the diagnostic yield of these organisms. Early
20. Lloveras J, Peterson PK, Simmons RL, Najarian JS: Mycobacte-institution of ATT can eliminate mortality caused by rial infections in renal transplant patients. Arch Intern Med
pulmonary tuberculosis. Low-dose cotrimoxazole pro- 142:888–892, 1982
21. Higgins RM, Cahn AP, Porter D, Richardson AJ, Mitchellphylaxis is effective in completely eliminating P. carinii
RG, Hopkin JM, Morris PJ: Mycobacterial infections after renalpneumonia and should be uniformly administered. transplantation. Q J Med 286:145–153, 1991
22. Coutts II, Jegarajah S, Stark JE: Tuberculosis in renal transplant
Reprint requests to Professor Vinay Sakhuja, Head, Department of recipients. Br J Dis Chest 73:141–148, 1979
Nephrology, Postgraduate Institute of Medical Education and Research, 23. Riska H, Gronhagen-Riska C, Ahonen J: Tuberculosis in renal
Chandigarh, 160012, India. allograft transplantation. Transplant Proc 19:4096–4097, 1987
24. McWhinney N, Khan O, Williams G: Tuberculosis in patients
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